Compare Stocks

→ Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FAB First Trust Multi Cap Value AlphaDEX Fund	$79.30 -0.5%	$79.30	$64.89 ▼ $82.62	$154.63M	1.22	5,496 shs	3,870 shs
IBIO iBio	$1.72 -9.5%	$0.00	$1.02 ▼ $23.60	$5.99M	-3.51	3.04 million shs	247,517 shs
TRIL Trillium Therapeutics	$18.44	$18.12	$5.80 ▼ $20.96	$1.94B	2.08	1.87 million shs	8 shs

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FAB First Trust Multi Cap Value AlphaDEX Fund	-0.01%	+3.04%	-1.04%	+3.70%	+17.94%
IBIO iBio	-1.05%	+0.53%	+50.00%	+188,999,900.00%	+188,999,900.00%
TRIL Trillium Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

How a $0.25 cent option contract makes my top traders feel (Ad)

If you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…

Click now to see for yourself what $0.25 Cent Trades is all about

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FAB First Trust Multi Cap Value AlphaDEX Fund	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRIL Trillium Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FAB First Trust Multi Cap Value AlphaDEX Fund	0.00	N/A	$87.28	10.07% Upside
IBIO iBio	N/A	N/A	N/A	N/A
TRIL Trillium Therapeutics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FAB First Trust Multi Cap Value AlphaDEX Fund	N/A	N/A	N/A	N/A	N/A	N/A
IBIO iBio	$2.38M	2.51	N/A	N/A	$15.15 per share	0.11
TRIL Trillium Therapeutics	$150K	12,907.39	N/A	N/A	$2.56 per share	7.20

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FAB First Trust Multi Cap Value AlphaDEX Fund	N/A	N/A	11.74	∞	N/A	N/A	N/A	N/A	N/A
IBIO iBio	-$65.01M	N/A	0.00	∞	N/A	N/A	-150.59%	-52.83%	N/A
TRIL Trillium Therapeutics	-$59.35M	$0.62	29.74	N/A	N/A	N/A	-23.31%	-18.66%	N/A

Latest TRIL, FAB, IMC, IBIO, and SUD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/9/2024	Q2 2024	IBIO iBio	N/A	-$2.42	-$2.42	-$0.42	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FAB First Trust Multi Cap Value AlphaDEX Fund	$1.48	1.87%	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A
TRIL Trillium Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest TRIL, FAB, IMC, IBIO, and SUD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/20/2024	FAB First Trust Multi Cap Value AlphaDEX Fund	Quarterly	$0.2430		3/21/2024	3/22/2024	3/28/2024

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FAB First Trust Multi Cap Value AlphaDEX Fund	N/A	N/A	N/A
IBIO iBio	0.04	0.91	0.91
TRIL Trillium Therapeutics	N/A	19.82	19.82

Ownership

Institutional Ownership

Company	Institutional Ownership
FAB First Trust Multi Cap Value AlphaDEX Fund	N/A
IBIO iBio	7.90%
TRIL Trillium Therapeutics	87.15%

Insider Ownership

Company	Insider Ownership
FAB First Trust Multi Cap Value AlphaDEX Fund	N/A
IBIO iBio	1.12%
TRIL Trillium Therapeutics	9.10%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
FAB First Trust Multi Cap Value AlphaDEX Fund	147,000	1.95 million	N/A	Not Optionable
IBIO iBio	26	3.48 million	3.45 million	N/A
TRIL Trillium Therapeutics	33	105.00 million	95.44 million	Optionable

TRIL, FAB, IMC, IBIO, and SUD Headlines

Source	Headline
	Cachet Bicycle shakes off COVID baytoday.ca - February 25 at 12:23 PM
	Rejuvenate your look with a trip to Fourth Avenue Medical Aesthetics chch.com - January 30 at 5:32 PM
	TTI apprehends motorists for illegal removal of clamps, hunt for four others underway bulawayo24.com - January 30 at 5:32 PM
	BridgeBio raises $1.25bn, and other biotech financings pharmaphorum.com - January 19 at 7:18 AM
	Ratio Therapeutics Raises $50M in Series B Financing precisionmedicineonline.com - January 17 at 1:39 PM
	Leiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.com businesswire.com - November 10 at 1:22 PM
	Mirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, Predictions benzinga.com - November 8 at 1:30 AM
	The Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast period uk.finance.yahoo.com - July 31 at 9:03 AM
	Ratio Therapeutics unveils new research and development facility biopharma-reporter.com - May 15 at 10:33 AM
	WHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: 'Can Cause Even Death' msn.com - April 26 at 12:18 AM
	Leukemia Therapeutics Global Market Report 2023 uk.finance.yahoo.com - April 4 at 10:35 AM
	Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck finance.yahoo.com - March 28 at 9:12 AM
	Trillium House, an affordable housing project in Warrenton, close to completion dailyastorian.com - January 10 at 12:26 AM
	FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinoma nz.finance.yahoo.com - October 19 at 9:39 AM
	Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment seekingalpha.com - September 14 at 9:48 AM
	Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors nz.finance.yahoo.com - September 12 at 7:55 AM
	Pfizer: Deal For Global Blood Therapeutics Carries Risk - More M&A Is Needed seekingalpha.com - August 17 at 11:07 AM
	TTI reviews parking model chronicle.co.zw - August 10 at 10:41 PM
	TTI working round the clock to configure its systems chronicle.co.zw - August 10 at 10:41 PM
	Pfizer in advanced talks to buy firm making sickle cell drugs pmnewsnigeria.com - August 7 at 3:57 AM
	10 Psychedelics CEOs To Pay Attention To In 2022 markets.businessinsider.com - June 22 at 10:08 AM
	Highlights from ASCO Annual Meeting 2022 healio.com - June 15 at 1:37 PM
	Chlormethine gel may be more effective than ointment for mycosis fungoides healio.com - May 27 at 4:34 PM
	Pfizer and Moderna created life-saving vaccines. So why are their stocks crumbling? edition.cnn.com - May 20 at 2:06 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Wall Street falls on double dose of disappointing economic data, as Meta sinks
April 25, 2024 2:14 AM
View Stock market today: Wall Street falls on double dose of disappointing economic data, as Meta sinks
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
Silicon Motion Proves That AI in Motion Stays in Motion
April 16, 2024 11:42 AM
View Silicon Motion Proves That AI in Motion Stays in Motion
Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?
April 10, 2024 7:55 AM
View Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?

All Headlines

Company Descriptions

First Trust Multi Cap Value AlphaDEX Fund

NASDAQ:FAB

The First Trust Multi Cap Value AlphaDEX Fund (FAB) is an exchange-traded fund that is based on the NASDAQ AlphaDEX Multi Cap Value index. The fund tracks an index that uses fundamental factors to select and weight value stocks from the Nasdaq US Select Indices. FAB was launched on May 8, 2007 and is managed by First Trust.

iBio

NYSE:IBIO

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

Trillium Therapeutics

NASDAQ:TRIL

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial